Comparative Pharmacology
Head-to-head clinical analysis: APIDRA SOLOSTAR versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA SOLOSTAR versus MERILOG SOLOSTAR.
APIDRA SOLOSTAR vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
0.5 mg subcutaneously once a day.
None Documented
None Documented
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category C
Category C
Insulin
Insulin